# Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Study · id `cardio:ct-nct06272487` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06272487](<https://clinicaltrials.gov/study/NCT06272487>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06272487

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.

## Technical summary

Registry record NCT06272487. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-29 (actual); primary completion 2025-06-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 375 participants (enrolled count; ClinicalTrials.gov record NCT06272487, source copy `cardio:ctgov-nct06272487-2026-03-02`, retrieved 2026-10-26)
- Started: 2024-02-29 (actual) (ClinicalTrials.gov record NCT06272487, source copy `cardio:ctgov-nct06272487-2026-03-02`, retrieved 2026-10-26)
- Primary completion: 2025-06-19 (actual) (ClinicalTrials.gov record NCT06272487, source copy `cardio:ctgov-nct06272487-2026-03-02`, retrieved 2026-10-26)
- Completion: 2025-12-01 (actual) (ClinicalTrials.gov record NCT06272487, source copy `cardio:ctgov-nct06272487-2026-03-02`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Puerto Rico; Switzerland; United Kingdom (ClinicalTrials.gov record NCT06272487, source copy `cardio:ctgov-nct06272487-2026-03-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06272487-2026-03-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
- Acronym: KARDIA-3
- Condition: High Cardiovascular Risk
- Condition: Hypertension
- Intervention (Drug): Zilebesiran
- Intervention (Drug): Placebo
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

## Provenance

Content hash: 9e370ffa6cb0522a9d89a207cb476fa37996cfd9edfb71417d3268b55281925f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
